In 206 patients having haploidentical stem-cell transplant, low-dose ruxolitinib instead of mycophenolate mofetil cut grade II–IV acute GVHD by day 100 (6·8% vs 36·9%; sHR 0·15). Grade 3–4 thrombocytopenia and neutropenia were more frequent with ruxolitinib.
RCTn = 206
Wu et al. Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial